|
nasdaq:fate
|
728310
|
Apr 21st, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
243.00
|
Open
|
|
Apr 20th, 2024 11:26PM
|
Apr 20th, 2024 11:26PM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 20th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
243.00
|
Open
|
|
Apr 19th, 2024 11:23PM
|
Apr 20th, 2024 04:58PM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 19th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
244.00
|
Open
|
|
Apr 18th, 2024 11:30PM
|
Apr 18th, 2024 11:30PM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 18th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
244.00
|
Open
|
|
Apr 17th, 2024 11:38PM
|
Apr 18th, 2024 06:18PM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 17th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
244.00
|
Open
|
|
Apr 16th, 2024 11:20PM
|
Apr 17th, 2024 02:43PM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 16th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
244.00
|
Open
|
|
Apr 15th, 2024 11:17PM
|
Apr 16th, 2024 11:00AM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 15th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
244.00
|
Open
|
|
Apr 14th, 2024 11:12PM
|
Apr 15th, 2024 04:40PM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 14th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
244.00
|
Open
|
|
Apr 13th, 2024 11:01PM
|
Apr 13th, 2024 11:01PM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 13th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
244.00
|
Open
|
|
Apr 12th, 2024 10:52PM
|
Apr 13th, 2024 11:27AM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:fate
|
728310
|
Apr 12th, 2024 12:00AM
|
Fate Therapeutics Inc.
|
20K
|
244.00
|
Open
|
|
Apr 11th, 2024 10:57PM
|
Apr 12th, 2024 08:22AM
|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
|
Open
|
stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
|
Open
|
12278 Scripps Summit Dr
|
San Diego
|
California
|
US
|
92131
|
|
Fate Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|